Lead Product(s): Zika-HX antigen
Therapeutic Area: Infections and Infectious Diseases Product Name: Zika vaccine
Highest Development Status: Undisclosed Product Type: Vaccine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership July 13, 2020
Excivion has partnered with CPI to draw upon the company’s extensive experience in the optimisation and scale-up of biologics manufacturing processes to optimise the manufacture of their novel Zika vaccine antigen candidate, Zika-HX.